Tirzepatide: Benefits, Dosage & FDA Status
Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
FDA Status
FDA-approved for weight management and type 2 diabetes
Typical Dose
2.5–15 mg weekly (subcutaneous injection)
Evidence Grade
A+Strong RCT evidence + FDA approval
Half-Life
~5 days
Routes of Administration
subcutaneous
First Synthesized
2018
Clinics Indexed
1,850 providers have offered Tirzepatide in our tracked directory.
Mechanism of Action
Dual agonist at GIP and GLP-1 receptors — combines incretin actions on insulin secretion, glucagon suppression, satiety, and adipose tissue.
Key Reported Benefits
- ✓Superior weight loss
- ✓Dual hormone targeting
- ✓Blood sugar control
- ✓Reduced cardiovascular risk
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade A+ indicates strong rct evidence + fda approval.
Reported Side Effects
- •Nausea
- •Vomiting
- •Constipation or diarrhea
- •Injection-site reactions
Contraindications
- ⚠Personal/family history of medullary thyroid carcinoma
- ⚠MEN-2 syndrome
- ⚠Pregnancy
Regulatory & Safety Context
FDA status: FDA-approved for weight management and type 2 diabetes
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on Tirzepatide. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
Semaglutide
A+A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
Liraglutide
A+The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
Retatrutide
ATriple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.
Cagrilintide
AA once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.
Survodutide
AA dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.
AOD-9604
C+A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.